With more than forty years of executive, general management, business development, sales, marketing, and technology commercialization experience, Mr. Sharp’s career spans private venture-backed businesses, mid-size and Fortune 100 public companies in the medical device, diagnostics and life science tools and services markets.
Mr. Sharp has served in senior leadership roles with five venture-backed companies—as Chief Executive Officer of CYTOO, Inc. and ArunA Biomedical, Chief Commercial Officer of BioProcessors Corporation (acquired by Seahorse Biosciences), SVP Business Development of Cellomics (acquired by Fisher International), and VP Business Development of Gentra Systems (acquired by Qiagen).
Earlier career includes senior leadership roles with Life Technologies, General Manager of Terumo Medical, Vice President of Sales and Marketing at Heraeus Instruments and roles of increasing responsibility within the diagnostics business of Baxter Healthcare and a medical device subsidiary of Eli Lilly. Mr. Sharp has successfully commercialized more than 500 products and services. Earned M.S. and B.A. degrees from the Pennsylvania State University.
Bringing over forty years of experience in the pharmaceutical, biomedical and biotechnology industries to ZyMot Fertility, Mr. Sly has global responsibility for marketing, regulatory, manufacturing and overall business operations. Prior to joining the team, Mr. Sly directed the commercial strategy, marketing and business development activities for Baltimore-based Paragon Bioservices. Throughout his career, Mr. Sly’s focus has primarily been strategic marketing and business development, from leading the efforts in pharmaceutical technology licensing and product development (including Phase I–III development and commercial manufacturing), to the development of business strategy and strategic commercial development for a range of biopharmaceutical products. Mr. Sly joined the Maryland business community in 2002 as Chief Business Officer for a private start-up, Advancis Pharmaceutical Corporation, playing a critical role in establishing a strong marketing presence, delivering key validating licensing and acquisition deals, serving on the core IPO deal team and leading the post-IPO efforts to establish the company’s first commercial operations. He received his B.A. in Biology (pre-med) from Pomona College.
Mr. Shippy has more than 25 years of experience advising MedTech, diversified healthcare, and other companies. He has served in a strategic finance role for companies at all stages of their lifecycles, from start-up to exit, including on an interim CFO basis. Mr. Shippy’s background includes not only public accounting and corporate finance, but also strategy consulting and investment banking. Mr. Shippy is the Founder and CEO of Audacity Investment Bankers, a boutique investment bank and management consulting firm that is dedicated to serving MedTech companies of all types, including FDA-approved medical device companies and contract manufacturers. Prior to founding Audacity, Mr. Shippy was a Partner and Director of Healthcare at Stout Investment Bank, one of the nation’s fastest growing middle-market investment banks. Prior to Stout, he served as an investment banker at Houlihan Lokey, one of the nation’s largest Wall Street investment banks. Prior to investment banking, he was a strategy consultant at Accenture. Mr. Shippy also worked at Epic Ventures, a former Draper Fisher Jurvetson affiliate and early-stage venture capital firm with a focus on investing in early-stage biotech and other disruptive technology ventures. He began his career as a licensed CPA at a major global public accounting firm. Mr. Shippy holds an M.B.A. in International Finance from Thunderbird, and a B.S. in Accountancy from Northern Illinois University.
Mr. Goroff brings over thirty years of diverse experience as a corporate lawyer, entrepreneur, and advisor to business and non-profit enterprises. He began his legal career at Wachtell Lipton Rosen & Katz, and from 1992-2007 was a partner at Milbank Tweed Hadley & McCloy in New York and London, where he focused on public and private M&A and financially complex private equity transactions. Since 2007, Mr. Goroff has engaged in a mix of business and mission-driven activities. He has been involved in several early-stage, impact-oriented enterprises as a founder, investor, advisor, or lawyer, and spent three years as a Senior Managing Director at Avenue Capital in a non-legal role on two SPAC transactions. Mr. Goroff has, in parallel, devoted substantial time to global health, international development, and anti-poverty matters. He holds a graduate degree in global public health and has served as a consultant to related public and private entities and projects. He has had roles in mission-driven enterprises, including governance roles in a highly prominent international NGO, and directs mission-driven venture investing for a substantial family foundation. Michael earned an AB from Harvard College and JD from Harvard Law School. In mid-career, he received an MPH from the Harvard School of Public Health, where he was subsequently a Takemi Fellow in International Health.
Mr. Giannetti is an accomplished sales leader with over twelve years of demonstrated success in the medical industry. He has worked side-by-side with hundreds of medical professional to help improve patient care by introducing new and efficacious treatment modalities. Mr. Giannetti has also supported the growth of his partners’ medical clinics by creating patient retention programs, executing marketing initiatives to attract new patients, as well as the implementation of new revenue streams. With experience ranging across multiple medical disciplines, in both large companies as well as multiple start-ups, Mr. Giannetti brings a broad scope of insight to the ZyMōt Fertility team. His passion for improving patient outcomes and being a true partner to our customers has been a welcomed addition since joining the team in January 2020. Mr. Giannetti earned his B.S. from Montclair State University.
Mr. Leer brings over twenty years of experience in reproductive medicine and women’s health to ZyMōt Fertility. Having established and managed sales distribution partnership networks in more than 65 countries throughout his career, as well as having developed and launched innovative products to the fertility market, Mr. Leer brings important depth and on-the-ground experience to the team as we continue our efforts to drive market penetration globally. Based out of the United Kingdom, Mr. Leer has held senior business development and sales management positions with market leading companies, such as Merck Serono, Cooper Origio and Igenomix. His earlier experiences involved establishing and managing sales, marketing and distribution capabilities for medical device products throughout Europe, Asia, the Middle East, the United States, and South America. Mr. Leer received his formal qualifications in Business and Finance from Portsmouth College in the UK.
Mr. Caban is a highly accomplished engineer with over 20 years of experience in the medical device industry. He specializes in developing, launching, and manufacturing innovative medical devices. Mr. Caban has the unique experience of having been directly responsible for taking designs from a pencil sketch through development and into high-volume manufacturing. He has worked for both large corporations (Texas Instruments, Motorola, Harris Corporation) as well as multiple early-stage companies. Mr. Caban is named on several issued patents, led the mechanical design of the world’s smallest glucose meter, named Sidekick, and was a key contributor to the successful launch and regulatory approval of the first long-term implantable glucose sensor, Eversense. He has also been responsible for the design and successful qualification of fully automated production and packaging lines. He earned a B.S. degree in Mechanical Engineering from the University of Florida and is a certified Lean Six Sigma Black Belt.
Co-Founder, Chairman and Chief Executive Officer
With more than forty years of executive, general management, business development, sales, marketing, and technology commercialization experience, Mr. Sharp’s career spans private venture-backed businesses, mid-size and Fortune 100 public companies in the medical device, diagnostics and life science tools and services markets.
Mr. Sharp has served in senior leadership roles with five venture-backed companies—as Chief Executive Officer of CYTOO, Inc. and ArunA Biomedical, Chief Commercial Officer of BioProcessors Corporation (acquired by Seahorse Biosciences), SVP Business Development of Cellomics (acquired by Fisher International), and VP Business Development of Gentra Systems (acquired by Qiagen).
Earlier career includes senior leadership roles with Life Technologies, General Manager of Terumo Medical, Vice President of Sales and Marketing at Heraeus Instruments and roles of increasing responsibility within the diagnostics business of Baxter Healthcare and a medical device subsidiary of Eli Lilly. Mr. Sharp has successfully commercialized more than 500 products and services. Earned M.S. and B.A. degrees from the Pennsylvania State University.
Chief Operating Officer
Bringing over forty years of experience in the pharmaceutical, biomedical and biotechnology industries to ZyMot Fertility, Mr. Sly has global responsibility for marketing, regulatory, manufacturing and overall business operations. Prior to joining the team, Mr. Sly directed the commercial strategy, marketing and business development activities for Baltimore-based Paragon Bioservices. Throughout his career, Mr. Sly’s focus has primarily been strategic marketing and business development, from leading the efforts in pharmaceutical technology licensing and product development (including Phase I–III development and commercial manufacturing), to the development of business strategy and strategic commercial development for a range of biopharmaceutical products. Mr. Sly joined the Maryland business community in 2002 as Chief Business Officer for a private start-up, Advancis Pharmaceutical Corporation, playing a critical role in establishing a strong marketing presence, delivering key validating licensing and acquisition deals, serving on the core IPO deal team and leading the post-IPO efforts to establish the company’s first commercial operations. He received his B.A. in Biology (pre-med) from Pomona College.
EVP and Chief Financial Officer
Mr. Shippy has more than 25 years of experience advising MedTech, diversified healthcare, and other companies. He has served in a strategic finance role for companies at all stages of their lifecycles, from start-up to exit, including on an interim CFO basis. Mr. Shippy’s background includes not only public accounting and corporate finance, but also strategy consulting and investment banking. Mr. Shippy is the Founder and CEO of Audacity Investment Bankers, a boutique investment bank and management consulting firm that is dedicated to serving MedTech companies of all types, including FDA-approved medical device companies and contract manufacturers. Prior to founding Audacity, Mr. Shippy was a Partner and Director of Healthcare at Stout Investment Bank, one of the nation’s fastest growing middle-market investment banks. Prior to Stout, he served as an investment banker at Houlihan Lokey, one of the nation’s largest Wall Street investment banks. Prior to investment banking, he was a strategy consultant at Accenture. Mr. Shippy also worked at Epic Ventures, a former Draper Fisher Jurvetson affiliate and early-stage venture capital firm with a focus on investing in early-stage biotech and other disruptive technology ventures. He began his career as a licensed CPA at a major global public accounting firm. Mr. Shippy holds an M.B.A. in International Finance from Thunderbird, and a B.S. in Accountancy from Northern Illinois University.
EVP and General Counsel
Mr. Goroff brings over thirty years of diverse experience as a corporate lawyer, entrepreneur, and advisor to business and non-profit enterprises. He began his legal career at Wachtell Lipton Rosen & Katz, and from 1992-2007 was a partner at Milbank Tweed Hadley & McCloy in New York and London, where he focused on public and private M&A and financially complex private equity transactions. Since 2007, Mr. Goroff has engaged in a mix of business and mission-driven activities. He has been involved in several early-stage, impact-oriented enterprises as a founder, investor, advisor, or lawyer, and spent three years as a Senior Managing Director at Avenue Capital in a non-legal role on two SPAC transactions. Mr. Goroff has, in parallel, devoted substantial time to global health, international development, and anti-poverty matters. He holds a graduate degree in global public health and has served as a consultant to related public and private entities and projects. He has had roles in mission-driven enterprises, including governance roles in a highly prominent international NGO, and directs mission-driven venture investing for a substantial family foundation. Michael earned an AB from Harvard College and JD from Harvard Law School. In mid-career, he received an MPH from the Harvard School of Public Health, where he was subsequently a Takemi Fellow in International Health.
Vice President of Sales, Human Fertility Market
Mr. Giannetti is an accomplished sales leader with over twelve years of demonstrated success in the medical industry. He has worked side-by-side with hundreds of medical professional to help improve patient care by introducing new and efficacious treatment modalities. Mr. Giannetti has also supported the growth of his partners’ medical clinics by creating patient retention programs, executing marketing initiatives to attract new patients, as well as the implementation of new revenue streams. With experience ranging across multiple medical disciplines, in both large companies as well as multiple start-ups, Mr. Giannetti brings a broad scope of insight to the ZyMōt Fertility team. His passion for improving patient outcomes and being a true partner to our customers has been a welcomed addition since joining the team in January 2020. Mr. Giannetti earned his B.S. from Montclair State University.
International Sales Director
Mr. Leer brings over twenty years of experience in reproductive medicine and women’s health to ZyMōt Fertility. Having established and managed sales distribution partnership networks in more than 65 countries throughout his career, as well as having developed and launched innovative products to the fertility market, Mr. Leer brings important depth and on-the-ground experience to the team as we continue our efforts to drive market penetration globally. Based out of the United Kingdom, Mr. Leer has held senior business development and sales management positions with market leading companies, such as Merck Serono, Cooper Origio and Igenomix. His earlier experiences involved establishing and managing sales, marketing and distribution capabilities for medical device products throughout Europe, Asia, the Middle East, the United States, and South America. Mr. Leer received his formal qualifications in Business and Finance from Portsmouth College in the UK.
Director, Product Development and Manufacturing
Mr. Caban is a highly accomplished engineer with over 20 years of experience in the medical device industry. He specializes in developing, launching, and manufacturing innovative medical devices. Mr. Caban has the unique experience of having been directly responsible for taking designs from a pencil sketch through development and into high-volume manufacturing. He has worked for both large corporations (Texas Instruments, Motorola, Harris Corporation) as well as multiple early-stage companies. Mr. Caban is named on several issued patents, led the mechanical design of the world’s smallest glucose meter, named Sidekick, and was a key contributor to the successful launch and regulatory approval of the first long-term implantable glucose sensor, Eversense. He has also been responsible for the design and successful qualification of fully automated production and packaging lines. He earned a B.S. degree in Mechanical Engineering from the University of Florida and is a certified Lean Six Sigma Black Belt.
With more than forty years of executive, general management, business development, sales, marketing, and technology commercialization experience, Mr. Sharp’s career spans private venture-backed businesses, mid-size and Fortune 100 public companies in the medical device, diagnostics and life science tools and services markets.
Mr. Sharp has served in senior leadership roles with five venture-backed companies—as Chief Executive Officer of CYTOO, Inc. and ArunA Biomedical, Chief Commercial Officer of BioProcessors Corporation (acquired by Seahorse Biosciences), SVP Business Development of Cellomics (acquired by Fisher International), and VP Business Development of Gentra Systems (acquired by Qiagen).
Earlier career includes senior leadership roles with Life Technologies, General Manager of Terumo Medical, Vice President of Sales and Marketing at Heraeus Instruments and roles of increasing responsibility within the diagnostics business of Baxter Healthcare and a medical device subsidiary of Eli Lilly. Mr. Sharp has successfully commercialized more than 500 products and services. Earned M.S. and B.A. degrees from the Pennsylvania State University.
Dr. Demirci is a Professor with tenure and Co-division Chief, Canary Center for Cancer Early Detection, Department of Radiology at Stanford University. Before moving to Stanford, he was Associate Professor of Medicine and Health Sciences and Technology at the Harvard Medical School (HMS) and Massachusetts Institute of Technology (MIT). He received a bachelor’s degree (summa cum laude) from the University of Michigan, Ann Arbor; master’s degrees in Electrical Engineering in 2001 and in Management Science and Engineering in 2005, as well as a PH.D. in Electrical Engineering in 2005 all from Stanford University. Dr. Demirci is an academic entrepreneur with seminal contributions to the development of innovative microfluidic platform technologies in medicine for broad applications in fertility, cell sorting, and point-of-care diagnostics. He is recipient of the Academy for Radiology & Biomedical Imaging Research (ARBIR) Distinguished Investigator Award; MIT TR-35 Award; Harvard Medical School-Young Investigator Award; Stanford Basic Scientist of the Year Award; Brigham and Women’s Hospital-Bright Future Award; IEEE EMBS Early Career Award; IEEE EMBS Translational Science Award; NSF CAREER Award; Coulter Foundation Early Career Award; and Chinese International Young Scientist Award. He holds 25 issued or pending patents, provisionals, and disclosures that have been licensed to companies. He has published 146 articles, 24 book chapters/editorials, and 4 edited books, and serves as an editorial board member for various peer-reviewed journals. Dr. Demirci is also a fellow-elect of American Institute of Medical and Biological Engineering (AIMBE).
John Jain, MD is the CEO and Medical Director of Santa Monica Fertility. Dr. Jain completed medical school, residency and Fellowship in Reproductive Endocrinology and Infertility at the University of Southern California (USC) before joining the medical faculty in the Department of Obstetrics and Gynecology. While on faculty Dr. Jain served as the Associate Director of the American Board Fellowship in Reproductive Endocrinology and Infertility and Fellowship Director for the Kenneth Ryan Fellowship in Contraception.
While at USC, Dr. Jain received over $8M in federal and industry grants. Among these were RO1 grants from the NIH and industry grants from Pharmacia, Pfizer and other well-known pharmaceutical leaders studying the clinical effects of various steroids on contraception and bleeding. Dr. Jain served three years on the Small Business Innovative Research (SBIR) committee of the NIH reviewing dozens of biotechnology grants for federal funding as well as several study groups in the Institute of Child Health and Human Development and as an advisor on the inaugural committee on fertility preservation co-sponsored by the National Cancer Institute. Dr. Jain also served on the Advisory Board of the Buffet Foundation Kenneth Ryan Fellowship.
Dr. Jain has published over 100 scientific works including landmark articles in the New England Journal of Medicine and Journal of the American Medical Association. He was the first to publish results of a clinical trial on oocyte cryopreservation which ultimately led to an invitation to debate the topic of oocyte cryopreservation at the annual meeting of the American Society of Reproductive Medicine in 2009. Dr. Jain created the egg freezing program at USC and founded The Donor Egg Bank in 2004, one of the first frozen donor egg banks in the world.
Dr. Jain left his tenured position at USC in 2007 to establish Santa Monica Fertility located in Santa Monica, California. Over the past decade Dr. Jain built Santa Monica Fertility into an internationally recognized center specializing in egg donation and surrogacy with annual sales over $25M. This growth was facilitated by Dr. Jain’s footprint on American television, having appeared on over 15 nationally broadcasted shows including the Today Show, CNN, Dr. Oz, and the Doctors and being featured in the 2012 PBS Documentary My Future Baby, an award-nominated, nationally broadcasted documentary on the state of modern infertility treatment.
Santa Monica Fertility was partly acquired by Webster Capital Partners in 2019. Webster subsequently acquired 7 other high-quality fertility clinics in key fertility markets in the US. These companies have been reorganized under Pinnacle Fertility now established as one of the largest fertility platforms in the US accounting for over 10,000 annual ART cycles. Dr. Jain is a member of the Board of Directors of Pinnacle Fertility. In this role, he primarily provides insight on the clinical and lab practice of ART and advises on integration of various ancillary services and products.
Dr. Jain is also the Founder of Novantacinque, a hospitality company with properties in the U.S. and Europe. Its first restaurant, Saso, was named one of the best new restaurants in Los Angeles in addition to being named on other international lists.
A serial investor in several healthcare technology startups, Ufuk Eren is the Founding Partner and CEO of Volitan Global. Volitan Global is based in 10 countries on 3 continents and is focused on technologies, innovation management, investment and M&A-like consulting services in the healthcare and life sciences sectors. Since July 2014, Mr. Eren has also held leading roles at Ernst & Young (EY) as Healthcare and Life Sciences Sector Leader for Turkey and Healthcare Sector Senior Advisor for Central, East, Southeast Europe and Central Asia (CESA). Mr. Eren has also been the Senior Advisor for the Healthcare and Life Sciences Sectors for Vodafone since October 2017.
From April 2014 to August 2016, Mr. Eren was Senior Advisor to the Royal Academy of Science International Trust (RASIT). In parallel, Mr. Eren was the founding partner and CEO of UK-based UN Innovation Development (UNID) company between June 2014 and August 2016. Mr. Eren had an active role in the “Women’s Health and Development Forum” organization, under the sponsorship of the United Nations together with UNID and RASIT in February 2015 at United Nations headquarters in New York City.
Throughout his career, Mr. Eren has held a number of senior leadership positions within the healthcare industry. Prior to his 20-year tenure with Siemens, he held management roles at International Hospital, Turkey and Canton Hospital in St. Gallen (KSSG), Switzerland. At Siemens, Mr. Eren held various roles such as CEO of the Clinical Products Division for Central Eastern Europe (CEE) and the Russia & Central Asia (RCA) Regions, CEO of South Asia Region, CEO of Siemens Healthcare Eastern Mediterranean Cluster and General Manager of Siemens Healthcare Turkey. Mr. Eren designed and implemented a training initiative as “Siemens Academy” which certified more than 1,000 professionals in the areas of “Health Management, Energy, Automation and Electrical Industries”. During his Siemens tenure, he established the Hospital Solutions Business, offering turn-key hospital solutions.
In 2013, Mr. Eren joined the Acıbadem Healthcare Group – part of IHH (the world’s second largest hospital group) as a member of the Executive Committee and assumed responsibilities such as Acıbadem’s investments and global growth, management of laboratory companies, strategy development for public-private partnership (PPP) projects and developing new business models. In addition, Mr. Eren has held various executive positions in a number of non-governmental organizations throughout his career and continues to actively pursue such opportunities.
Mr. Eren contributes to the realization of the visionary meetings for the development of the healthcare sector in Turkey at TUSAP (Turkish Healthcare Platform) of which he is among the founders and is currently a member of the Executive Committee. He also gives Health Economics and Entrepreneurship lectures as a visiting professor at Bahcesehir University Health Sciences Institute and is a member of the Advisory Board at Hacettepe University Health Economics and Health Policies Research and Implementation Center.
Co-Founder, Chairman and Chief Executive Officer
With more than forty years of executive, general management, business development, sales, marketing, and technology commercialization experience, Mr. Sharp’s career spans private venture-backed businesses, mid-size and Fortune 100 public companies in the medical device, diagnostics and life science tools and services markets.
Mr. Sharp has served in senior leadership roles with five venture-backed companies—as Chief Executive Officer of CYTOO, Inc. and ArunA Biomedical, Chief Commercial Officer of BioProcessors Corporation (acquired by Seahorse Biosciences), SVP Business Development of Cellomics (acquired by Fisher International), and VP Business Development of Gentra Systems (acquired by Qiagen).
Earlier career includes senior leadership roles with Life Technologies, General Manager of Terumo Medical, Vice President of Sales and Marketing at Heraeus Instruments and roles of increasing responsibility within the diagnostics business of Baxter Healthcare and a medical device subsidiary of Eli Lilly. Mr. Sharp has successfully commercialized more than 500 products and services. Earned M.S. and B.A. degrees from the Pennsylvania State University.
Co-founder, Director, Scientific Advisor
Dr. Demirci is a Professor with tenure and Co-division Chief, Canary Center for Cancer Early Detection, Department of Radiology at Stanford University. Before moving to Stanford, he was Associate Professor of Medicine and Health Sciences and Technology at the Harvard Medical School (HMS) and Massachusetts Institute of Technology (MIT). He received a bachelor’s degree (summa cum laude) from the University of Michigan, Ann Arbor; master’s degrees in Electrical Engineering in 2001 and in Management Science and Engineering in 2005, as well as a PH.D. in Electrical Engineering in 2005 all from Stanford University. Dr. Demirci is an academic entrepreneur with seminal contributions to the development of innovative microfluidic platform technologies in medicine for broad applications in fertility, cell sorting, and point-of-care diagnostics. He is recipient of the Academy for Radiology & Biomedical Imaging Research (ARBIR) Distinguished Investigator Award; MIT TR-35 Award; Harvard Medical School-Young Investigator Award; Stanford Basic Scientist of the Year Award; Brigham and Women’s Hospital-Bright Future Award; IEEE EMBS Early Career Award; IEEE EMBS Translational Science Award; NSF CAREER Award; Coulter Foundation Early Career Award; and Chinese International Young Scientist Award. He holds 25 issued or pending patents, provisionals, and disclosures that have been licensed to companies. He has published 146 articles, 24 book chapters/editorials, and 4 edited books, and serves as an editorial board member for various peer-reviewed journals. Dr. Demirci is also a fellow-elect of American Institute of Medical and Biological Engineering (AIMBE).
Director
John Jain, MD is the CEO and Medical Director of Santa Monica Fertility. Dr. Jain completed medical school, residency and Fellowship in Reproductive Endocrinology and Infertility at the University of Southern California (USC) before joining the medical faculty in the Department of Obstetrics and Gynecology. While on faculty Dr. Jain served as the Associate Director of the American Board Fellowship in Reproductive Endocrinology and Infertility and Fellowship Director for the Kenneth Ryan Fellowship in Contraception.
While at USC, Dr. Jain received over $8M in federal and industry grants. Among these were RO1 grants from the NIH and industry grants from Pharmacia, Pfizer and other well-known pharmaceutical leaders studying the clinical effects of various steroids on contraception and bleeding. Dr. Jain served three years on the Small Business Innovative Research (SBIR) committee of the NIH reviewing dozens of biotechnology grants for federal funding as well as several study groups in the Institute of Child Health and Human Development and as an advisor on the inaugural committee on fertility preservation co-sponsored by the National Cancer Institute. Dr. Jain also served on the Advisory Board of the Buffet Foundation Kenneth Ryan Fellowship.
Dr. Jain has published over 100 scientific works including landmark articles in the New England Journal of Medicine and Journal of the American Medical Association. He was the first to publish results of a clinical trial on oocyte cryopreservation which ultimately led to an invitation to debate the topic of oocyte cryopreservation at the annual meeting of the American Society of Reproductive Medicine in 2009. Dr. Jain created the egg freezing program at USC and founded The Donor Egg Bank in 2004, one of the first frozen donor egg banks in the world.
Dr. Jain left his tenured position at USC in 2007 to establish Santa Monica Fertility located in Santa Monica, California. Over the past decade Dr. Jain built Santa Monica Fertility into an internationally recognized center specializing in egg donation and surrogacy with annual sales over $25M. This growth was facilitated by Dr. Jain’s footprint on American television, having appeared on over 15 nationally broadcasted shows including the Today Show, CNN, Dr. Oz, and the Doctors and being featured in the 2012 PBS Documentary My Future Baby, an award-nominated, nationally broadcasted documentary on the state of modern infertility treatment.
Santa Monica Fertility was partly acquired by Webster Capital Partners in 2019. Webster subsequently acquired 7 other high-quality fertility clinics in key fertility markets in the US. These companies have been reorganized under Pinnacle Fertility now established as one of the largest fertility platforms in the US accounting for over 10,000 annual ART cycles. Dr. Jain is a member of the Board of Directors of Pinnacle Fertility. In this role, he primarily provides insight on the clinical and lab practice of ART and advises on integration of various ancillary services and products.
Dr. Jain is also the Founder of Novantacinque, a hospitality company with properties in the U.S. and Europe. Its first restaurant, Saso, was named one of the best new restaurants in Los Angeles in addition to being named on other international lists.
Director
A serial investor in several healthcare technology startups, Ufuk Eren is the Founding Partner and CEO of Volitan Global. Volitan Global is based in 10 countries on 3 continents and is focused on technologies, innovation management, investment and M&A-like consulting services in the healthcare and life sciences sectors. Since July 2014, Mr. Eren has also held leading roles at Ernst & Young (EY) as Healthcare and Life Sciences Sector Leader for Turkey and Healthcare Sector Senior Advisor for Central, East, Southeast Europe and Central Asia (CESA). Mr. Eren has also been the Senior Advisor for the Healthcare and Life Sciences Sectors for Vodafone since October 2017.
From April 2014 to August 2016, Mr. Eren was Senior Advisor to the Royal Academy of Science International Trust (RASIT). In parallel, Mr. Eren was the founding partner and CEO of UK-based UN Innovation Development (UNID) company between June 2014 and August 2016. Mr. Eren had an active role in the “Women’s Health and Development Forum” organization, under the sponsorship of the United Nations together with UNID and RASIT in February 2015 at United Nations headquarters in New York City.
Throughout his career, Mr. Eren has held a number of senior leadership positions within the healthcare industry. Prior to his 20-year tenure with Siemens, he held management roles at International Hospital, Turkey and Canton Hospital in St. Gallen (KSSG), Switzerland. At Siemens, Mr. Eren held various roles such as CEO of the Clinical Products Division for Central Eastern Europe (CEE) and the Russia & Central Asia (RCA) Regions, CEO of South Asia Region, CEO of Siemens Healthcare Eastern Mediterranean Cluster and General Manager of Siemens Healthcare Turkey. Mr. Eren designed and implemented a training initiative as “Siemens Academy” which certified more than 1,000 professionals in the areas of “Health Management, Energy, Automation and Electrical Industries”. During his Siemens tenure, he established the Hospital Solutions Business, offering turn-key hospital solutions.
In 2013, Mr. Eren joined the Acıbadem Healthcare Group – part of IHH (the world’s second largest hospital group) as a member of the Executive Committee and assumed responsibilities such as Acıbadem’s investments and global growth, management of laboratory companies, strategy development for public-private partnership (PPP) projects and developing new business models. In addition, Mr. Eren has held various executive positions in a number of non-governmental organizations throughout his career and continues to actively pursue such opportunities.
Mr. Eren contributes to the realization of the visionary meetings for the development of the healthcare sector in Turkey at TUSAP (Turkish Healthcare Platform) of which he is among the founders and is currently a member of the Executive Committee. He also gives Health Economics and Entrepreneurship lectures as a visiting professor at Bahcesehir University Health Sciences Institute and is a member of the Advisory Board at Hacettepe University Health Economics and Health Policies Research and Implementation Center.
Marlane received her PhD in Physiology from Auburn University in 1983. She completed two NIH-funded postdoctoral fellowships at the University of Texas Health Science Center, San Antonio, TX, and Southwestern Medical School, Dallas, TX. She trained in IVF at the University of California, San Francisco, became a High Complexity Laboratory Director in 1995 and has directed IVF programs in Albuquerque, NM; Asheville, NC; Greensboro, and Winston-Salem, NC; Las Vegas, NV; Little Rock, AR; Phoenix, AZ; Rochester, NY; San Francisco, CA; and Seattle, WA. She has worked as a consultant with multiple companies, including Irvine Scientific, Previvo Genetics, DxNow/ZyMōt Fertility and the World Egg Bank. Marlane also teaches in both the Masters and PhD programs at Eastern Virginia Medical School. She has published more than 70 papers, abstracts and chapters, and is one of the founders, and currently President of the Board of Directors, for the Southwest Embryology Summit.
Mary has over 35 years of experience as a healthcare leader, respected for advancing patient care with science in Reproductive Medicine and Endocrinology. She completed her PhD training jointly at Old Dominion University and the Jones Institute at Eastern Virginia Medical School (EVMS). During an Andrew Mellon Foundation postdoctoral fellowship, she focused her preclinical and clinical research on human sperm pre-fertilization capacitation events on the cellular level, including intracellular signaling occurring during hyperactivated motility, acrosome reaction and sperm-zona binding. Mary split her professional career between academia and the pharmaceutical/biotechnology industry. She rose to the rank of Associate Professor and Division Director, Reproductive Sciences, in the Department of Obstetrics and Gynecology at EVMS, and adjunct Associate Professor in the Department of Biological Sciences at ODU. She maintained a fully-supported research program with funding from NIH/NICHD, foundations and pharmaceutical/biotech companies, mentored the research efforts of graduate students and reproductive endocrinology fellows, and was certified as a High Complexity Laboratory. Upon leaving academia, Mary spent 20 years in pharmaceutical industry in positions of increasing responsibilities, the last at EMD Serono as Vice President, Fertility and Endocrinology, US Medical Affairs, where she was responsible for leading the medical team and its medical strategy for both pharmaceutical products and their devices and IVF laboratory medical devices. She has authored/co-authored more than 53 full publications in peer-reviewed journals with 103 published abstracts presented at national/international meetings.
With more than 10,000 in vitro fertilization cycles and nearly 25 years of experience, Tony continues to lead the laboratory in success rates that exceed the national average as reported to the CDC and SART every year. Tony completed his Master’s in Clinical Embryology studies at University of Leeds, Leeds, England, under the direction of many pioneers of the first IVF baby, Louise Brown. He is a Certified Embryology Laboratory Director (ABB) who has lectured and presented at conferences nationwide, published papers on embryonic development, cryopreservation, and genomics and received several honors and distinctions. His expertise is sought by other laboratories internationally and within the USA.
An embryologist and medical technologist with over 20 years of experience in reproductive technology, Cynthia possesses a holistic industry perspective resulting from her diverse and comprehensive background: She has worked in a number of the nation’s foremost IVF practices and designed multiple IVF laboratories, in addition to founding and operating innovative reproductive medicine centers. Cynthia is currently VP Clinical Strategy at TMRW Life Sciences. Prior to TMRW, Cynthia was Founder and CEO of Manhattan Fertility Services, a full-service fertility center with an in-house IVF lab. Cynthia built and operated the practice while developing a pioneering patient experience and viable revenue streams. Her creation of a reference andrology lab, management corporation, and associated medical practice played a critical role in the center’s growth and eventual sale. She applied this same holistic expertise as co-Founder of Kindbody — a revolutionary reproductive firm that combines best-in-class technology, clinical excellence, and accessible pricing to connect the full patient experience on one intuitive platform. As Founder and CEO of Cellavita, an Assisted Reproductive Technology consulting service established in 2004, Cynthia offered a variety of advisory and laboratory services to a wide range of corporate clients and domestic and international clinical IVF programs. Cynthia is a member of multiple medical organizations, including the American Board of Bioanalysis, American Society for Reproductive Medicine, and American College of Embryology. She is an active researcher, and she has made dozens of published contributions to leading scientific journals, such as Fertility & Sterility, Human Reproduction, and Science. Her work has also been featured in presentations at the American Society for Reproductive Medicine and European Society for Human Reproduction and Embryology.
Marlane received her PhD in Physiology from Auburn University in 1983. She completed two NIH-funded postdoctoral fellowships at the University of Texas Health Science Center, San Antonio, TX, and Southwestern Medical School, Dallas, TX. She trained in IVF at the University of California, San Francisco, became a High Complexity Laboratory Director in 1995 and has directed IVF programs in Albuquerque, NM; Asheville, NC; Greensboro, and Winston-Salem, NC; Las Vegas, NV; Little Rock, AR; Phoenix, AZ; Rochester, NY; San Francisco, CA; and Seattle, WA. She has worked as a consultant with multiple companies, including Irvine Scientific, Previvo Genetics, DxNow/ZyMōt Fertility and the World Egg Bank. Marlane also teaches in both the Masters and PhD programs at Eastern Virginia Medical School. She has published more than 70 papers, abstracts and chapters, and is one of the founders, and currently President of the Board of Directors, for the Southwest Embryology Summit.
Mary has over 35 years of experience as a healthcare leader, respected for advancing patient care with science in Reproductive Medicine and Endocrinology. She completed her PhD training jointly at Old Dominion University and the Jones Institute at Eastern Virginia Medical School (EVMS). During an Andrew Mellon Foundation postdoctoral fellowship, she focused her preclinical and clinical research on human sperm pre-fertilization capacitation events on the cellular level, including intracellular signaling occurring during hyperactivated motility, acrosome reaction and sperm-zona binding. Mary split her professional career between academia and the pharmaceutical/biotechnology industry. She rose to the rank of Associate Professor and Division Director, Reproductive Sciences, in the Department of Obstetrics and Gynecology at EVMS, and adjunct Associate Professor in the Department of Biological Sciences at ODU. She maintained a fully-supported research program with funding from NIH/NICHD, foundations and pharmaceutical/biotech companies, mentored the research efforts of graduate students and reproductive endocrinology fellows, and was certified as a High Complexity Laboratory. Upon leaving academia, Mary spent 20 years in pharmaceutical industry in positions of increasing responsibilities, the last at EMD Serono as Vice President, Fertility and Endocrinology, US Medical Affairs, where she was responsible for leading the medical team and its medical strategy for both pharmaceutical products and their devices and IVF laboratory medical devices. She has authored/co-authored more than 53 full publications in peer-reviewed journals with 103 published abstracts presented at national/international meetings.
With more than 10,000 in vitro fertilization cycles and nearly 25 years of experience, Tony continues to lead the laboratory in success rates that exceed the national average as reported to the CDC and SART every year. Tony completed his Master’s in Clinical Embryology studies at University of Leeds, Leeds, England, under the direction of many pioneers of the first IVF baby, Louise Brown. He is a Certified Embryology Laboratory Director (ABB) who has lectured and presented at conferences nationwide, published papers on embryonic development, cryopreservation, and genomics and received several honors and distinctions. His expertise is sought by other laboratories internationally and within the USA.
An embryologist and medical technologist with over 20 years of experience in reproductive technology, Cynthia possesses a holistic industry perspective resulting from her diverse and comprehensive background: She has worked in a number of the nation’s foremost IVF practices and designed multiple IVF laboratories, in addition to founding and operating innovative reproductive medicine centers. Cynthia is currently VP Clinical Strategy at TMRW Life Sciences. Prior to TMRW, Cynthia was Founder and CEO of Manhattan Fertility Services, a full-service fertility center with an in-house IVF lab. Cynthia built and operated the practice while developing a pioneering patient experience and viable revenue streams. Her creation of a reference andrology lab, management corporation, and associated medical practice played a critical role in the center’s growth and eventual sale. She applied this same holistic expertise as co-Founder of Kindbody — a revolutionary reproductive firm that combines best-in-class technology, clinical excellence, and accessible pricing to connect the full patient experience on one intuitive platform. As Founder and CEO of Cellavita, an Assisted Reproductive Technology consulting service established in 2004, Cynthia offered a variety of advisory and laboratory services to a wide range of corporate clients and domestic and international clinical IVF programs. Cynthia is a member of multiple medical organizations, including the American Board of Bioanalysis, American Society for Reproductive Medicine, and American College of Embryology. She is an active researcher, and she has made dozens of published contributions to leading scientific journals, such as Fertility & Sterility, Human Reproduction, and Science. Her work has also been featured in presentations at the American Society for Reproductive Medicine and European Society for Human Reproduction and Embryology.
Utkan Demirci is a Professor with tenure and Co-division Chief, Canary Center for Cancer Early Detection, Department of Radiology at Stanford University. Before moving to Stanford, he was Associate Professor of Medicine and Health Sciences and Technology at the Harvard Medical School (HMS) and Massachusetts Institute of Technology (MIT). He received a bachelor’s degree (summa cum laude) from the University of Michigan, Ann Arbor; master’s degrees in Electrical Engineering in 2001 and in Management Science and Engineering in 2005, as well as a PH.D. in Electrical Engineering in 2005 all from Stanford University. Utkan is an academic entrepreneur with seminal contributions to the development of innovative microfluidic platform technologies in medicine for broad applications in fertility, cell sorting, and point-of-care diagnostics. He is recipient of the Academy for Radiology & Biomedical Imaging Research (ARBIR) Distinguished Investigator Award; MIT TR-35 Award; Harvard Medical School-Young Investigator Award; Stanford Basic Scientist of the Year Award; Brigham and Women’s Hospital-Bright Future Award; IEEE EMBS Early Career Award; IEEE EMBS Translational Science Award; NSF CAREER Award; Coulter Foundation Early Career Award; and Chinese International Young Scientist Award. He holds 25 issued or pending patents, provisionals, and disclosures that have been licensed to companies. He has published 146 articles, 24 book chapters/editorials, and 4 edited books, and serves as an editorial board member for various peer-reviewed journals. Utkan is also a fellow-elect of American Institute of Medical and Biological Engineering (AIMBE).
Barry Behr is the Director of the IVF/ART Laboratory and Co-Director of the REI-IVF program, both at Stanford University, and is the Director of the Renew Biobank Institute for Stem Cell Biology and Regenerative Medicine. Barry is a nationally and internationally renowned clinical and scientific leader in the research and advances of human reproduction. As a world-renowned scientist and lecturer, he is highly sought after to chair scientific programs and conferences, is the first non-M.D. President of the Pacific Coast Reproductive Society and has been appointed as program chairman of several professional meetings. Barry has been widely recognized for his research and has published over 200 peer-reviewed publications and book chapters.
Dr. Palermo is the pioneer of intracytoplasmic sperm injection (ICSI), a ground-breaking technique that has transformed the treatment of male-factor infertility and fertilization failure. Ever since its inception in 1992, ICSI has assisted thousands of men to achieve biologic paternity. Beginning 1993, Dr. Palermo has been the Director of Assisted Fertilization and Andrology at the Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, one of the world’s largest ICSI programs. In his capacity as the Blavatnik Distinguished Professor of Reproductive Medicine, he leads a talented team of researchers comprising of andrologists and clinical fellows who investigate the molecular aspects of fertilization, genetic and epigenetic aspects of male infertility, follow-up of ICSI babies and the development and differentiation of embryonic stem cells. He has published over 76 book chapters, 327 abstracts, and 132 research papers, which have been featured in journals such as the New England Journal of Medicine, Lancet, JAMA, Human Reproduction, Fertility and Sterility, and PLOS One. He is the recipient of multiple awards, including the Jacob Heskel Gabbay Award in Biotechnology and Medicine awarded by the Rosenstiel Basic Medical Sciences Research Center and Brandeis University, the Barbara Eck Menning Founders Award, and the Francavilla Fontana Illustrious Citizen Award.
Dr. Polan served as chair of the Department of Obstetrics and Gynecology at the Stanford University School of Medicine from 1990 to 2006 and is currently Professor of Clinical Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine. Dr. Polan specializes in reproductive endocrinology and infertility and hormonal issues related to gynecology patients and menopause. She received her bachelor’s degree from Connecticut College and her Ph.D. in Molecular Biophysics and Biochemistry and M.D. from Yale University and completed her residency and Reproductive Endocrine Fellowship in the Department of Obstetrics and Gynecology at the Yale University School of Medicine. Dr. Polan received her M.P.H. (Maternal and Child Health Program) from the University of California, Berkeley. Her research has involved ovarian and urologic function with many publications in both areas. She is a member of the National Academy of Medicine, a part of the National Academy of Sciences and has served on a number of NIH and university committees. She has a long-standing interest in women’s health research and has been actively involved in international public health.
Dr. Rosen serves on the faculty at UCSF and is the Director of the UCSF Reproductive Laboratories and Fertility Preservation Program, one of the largest programs in the USA. He received his medical training at St. Louis University and completed his residency in Obstetrics and Gynecology at the University of Texas Medical Branch. Dr. Rosen subsequently received his training in Reproductive Endocrinology and Infertility at UCSF. He is board certified in both Obstetrics and Gynecology and Reproductive Endocrinology and Infertility. In addition, to further understand the IVF process, he also trained as an embryologist and serves as the laboratory director at UCSF. Knowledge of both the clinical and laboratory aspects of assisted reproduction has allowed him to focus his clinical work and research endeavors on optimizing IVF outcomes, and preserving fertility. As a result of his work, he has published numerous manuscripts and chapters that have significantly contributed to the field.
Dr. Turek is a board-certified urologist and microsurgeon, specializing in male fertility. He has performed and published research in men’s reproductive health issues including genetic infertility, ejaculatory duct obstruction, immunologic infertility, quality of life issues with infertility, testis cancer and stem cell science, and has developed several techniques for evaluating and treating male infertility. While at UCSF, he was Director of the Male Reproductive Clinical Laboratory, Program Leader of PROGENI (The Program in the Genetics of Infertility), Director of the UCSF Men’s Reproductive Health Clinic and Research Program, and the director of a National Institutes of Health grant to train new faculty in men’s reproductive health. He has authored more than 175 publications on clinical and scientific issues in reproductive health. Through his published work, he is a proponent of the theory that male infertility is an early marker for other diseases that occur later in life. He became a full professor, with an endowed chair in teaching funded by the Academy at UCSF, a chair he later abandoned in favor of starting his own private clinic. He is now Director of The Turek Clinic, a medical center that specializes exclusively in men’s reproductive health care. The clinic is dedicated to treating the unique conditions that affect reproductive age men. He was President in 2011 of the American Society of Andrology.
DxNow Co-founder, Director, Scientific Advisor
Utkan Demirci is a Professor with tenure and Co-division Chief, Canary Center for Cancer Early Detection, Department of Radiology at Stanford University. Before moving to Stanford, he was Associate Professor of Medicine and Health Sciences and Technology at the Harvard Medical School (HMS) and Massachusetts Institute of Technology (MIT). He received a bachelor’s degree (summa cum laude) from the University of Michigan, Ann Arbor; master’s degrees in Electrical Engineering in 2001 and in Management Science and Engineering in 2005, as well as a PH.D. in Electrical Engineering in 2005 all from Stanford University. Utkan is an academic entrepreneur with seminal contributions to the development of innovative microfluidic platform technologies in medicine for broad applications in fertility, cell sorting, and point-of-care diagnostics. He is recipient of the Academy for Radiology & Biomedical Imaging Research (ARBIR) Distinguished Investigator Award; MIT TR-35 Award; Harvard Medical School-Young Investigator Award; Stanford Basic Scientist of the Year Award; Brigham and Women’s Hospital-Bright Future Award; IEEE EMBS Early Career Award; IEEE EMBS Translational Science Award; NSF CAREER Award; Coulter Foundation Early Career Award; and Chinese International Young Scientist Award. He holds 25 issued or pending patents, provisionals, and disclosures that have been licensed to companies. He has published 146 articles, 24 book chapters/editorials, and 4 edited books, and serves as an editorial board member for various peer-reviewed journals. Utkan is also a fellow-elect of American Institute of Medical and Biological Engineering (AIMBE).
DxNow Clinical Advisory Board member
Barry Behr is the Director of the IVF/ART Laboratory and Co-Director of the REI-IVF program, both at Stanford University, and is the Director of the Renew Biobank Institute for Stem Cell Biology and Regenerative Medicine. Barry is a nationally and internationally renowned clinical and scientific leader in the research and advances of human reproduction. As a world-renowned scientist and lecturer, he is highly sought after to chair scientific programs and conferences, is the first non-M.D. President of the Pacific Coast Reproductive Society and has been appointed as program chairman of several professional meetings. Barry has been widely recognized for his research and has published over 200 peer-reviewed publications and book chapters.
DxNow Clinical Advisory Board member
Dr. Palermo is the pioneer of intracytoplasmic sperm injection (ICSI), a ground-breaking technique that has transformed the treatment of male-factor infertility and fertilization failure. Ever since its inception in 1992, ICSI has assisted thousands of men to achieve biologic paternity. Beginning 1993, Dr. Palermo has been the Director of Assisted Fertilization and Andrology at the Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, one of the world’s largest ICSI programs. In his capacity as the Blavatnik Distinguished Professor of Reproductive Medicine, he leads a talented team of researchers comprising of andrologists and clinical fellows who investigate the molecular aspects of fertilization, genetic and epigenetic aspects of male infertility, follow-up of ICSI babies and the development and differentiation of embryonic stem cells. He has published over 76 book chapters, 327 abstracts, and 132 research papers, which have been featured in journals such as the New England Journal of Medicine, Lancet, JAMA, Human Reproduction, Fertility and Sterility, and PLOS One. He is the recipient of multiple awards, including the Jacob Heskel Gabbay Award in Biotechnology and Medicine awarded by the Rosenstiel Basic Medical Sciences Research Center and Brandeis University, the Barbara Eck Menning Founders Award, and the Francavilla Fontana Illustrious Citizen Award.
DxNow Clinical Advisory Board member
Dr. Polan served as chair of the Department of Obstetrics and Gynecology at the Stanford University School of Medicine from 1990 to 2006 and is currently Professor of Clinical Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine. Dr. Polan specializes in reproductive endocrinology and infertility and hormonal issues related to gynecology patients and menopause. She received her bachelor’s degree from Connecticut College and her Ph.D. in Molecular Biophysics and Biochemistry and M.D. from Yale University and completed her residency and Reproductive Endocrine Fellowship in the Department of Obstetrics and Gynecology at the Yale University School of Medicine. Dr. Polan received her M.P.H. (Maternal and Child Health Program) from the University of California, Berkeley. Her research has involved ovarian and urologic function with many publications in both areas. She is a member of the National Academy of Medicine, a part of the National Academy of Sciences and has served on a number of NIH and university committees. She has a long-standing interest in women’s health research and has been actively involved in international public health.
DxNow Clinical Advisory Board member
Dr. Rosen serves on the faculty at UCSF and is the Director of the UCSF Reproductive Laboratories and Fertility Preservation Program, one of the largest programs in the USA. He received his medical training at St. Louis University and completed his residency in Obstetrics and Gynecology at the University of Texas Medical Branch. Dr. Rosen subsequently received his training in Reproductive Endocrinology and Infertility at UCSF. He is board certified in both Obstetrics and Gynecology and Reproductive Endocrinology and Infertility. In addition, to further understand the IVF process, he also trained as an embryologist and serves as the laboratory director at UCSF. Knowledge of both the clinical and laboratory aspects of assisted reproduction has allowed him to focus his clinical work and research endeavors on optimizing IVF outcomes, and preserving fertility. As a result of his work, he has published numerous manuscripts and chapters that have significantly contributed to the field.
DxNow Clinical Advisory Board member
Dr. Turek is a board-certified urologist and microsurgeon, specializing in male fertility. He has performed and published research in men’s reproductive health issues including genetic infertility, ejaculatory duct obstruction, immunologic infertility, quality of life issues with infertility, testis cancer and stem cell science, and has developed several techniques for evaluating and treating male infertility. While at UCSF, he was Director of the Male Reproductive Clinical Laboratory, Program Leader of PROGENI (The Program in the Genetics of Infertility), Director of the UCSF Men’s Reproductive Health Clinic and Research Program, and the director of a National Institutes of Health grant to train new faculty in men’s reproductive health. He has authored more than 175 publications on clinical and scientific issues in reproductive health. Through his published work, he is a proponent of the theory that male infertility is an early marker for other diseases that occur later in life. He became a full professor, with an endowed chair in teaching funded by the Academy at UCSF, a chair he later abandoned in favor of starting his own private clinic. He is now Director of The Turek Clinic, a medical center that specializes exclusively in men’s reproductive health care. The clinic is dedicated to treating the unique conditions that affect reproductive age men. He was President in 2011 of the American Society of Andrology.
